Pharmaceutical giant Johnson & Johnson is facing a lawsuit for allegedly using copyrighted music without permission in numerous online videos. Associated Production Music (APM) claims Johnson & Johnson used nearly 80 videos featuring unlicensed tracks, potentially facing significant financial penalties if found guilty.
Johnson & Johnson’s Rybrevant, a lung cancer treatment, continues to demonstrate positive results. A new study shows that a prophylactic strategy significantly reduces infusion-related reactions, while long-term data from the MARIPOSA study reinforces Rybrevant’s effectiveness in combination with Lazcluze, improving survival and disease control compared to standard treatment.
Johnson & Johnson has been ordered to pay $1 billion in damages to Auris Health shareholders for failing to meet commitments in a 2019 acquisition agreement. The Delaware Court of Chancery found that J&J’s actions hindered the development of Auris’ iPlatform technology, which was crucial for earning additional payments to investors.
Johnson & Johnson (JNJ) has achieved a ‘Golden Cross’, a technical indicator suggesting a shift from a bearish to a bullish trend. The stock’s 50-day moving average has crossed above the 200-day moving average, indicating strong upward momentum. This bullish signal is further supported by strong short-term strength and positive fundamental catalysts like the FDA submission for a new muscle weakness drug.
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA seeking approval for nipocalimab, an investigational treatment for generalized myasthenia gravis (gMG). This would mark the first FDA approval for nipocalimab globally. The application is based on positive results from the Phase 3 Vivacity-MG3 study, which showed that nipocalimab plus standard of care was superior to placebo plus standard of care in a broad population of antibody-positive gMG patients.
Johnson & Johnson is expected to confirm a $6.48 billion settlement to resolve thousands of lawsuits alleging that its baby powder products cause cancer. The settlement plan requires the approval of over 75% of claimants, which has reportedly been reached. This will involve a subsidiary of Johnson & Johnson filing for bankruptcy protection to finalize the agreement. This represents a renewed effort by the company to resolve long-standing talc litigation after previous attempts were rejected by courts.
Johnson & Johnson has taken a significant step towards resolving thousands of lawsuits alleging its baby powder caused cancer. Over 75% of plaintiffs have agreed to a $6.5 billion settlement proposal, potentially leading to a Chapter 11 bankruptcy filing and a 25-year payout plan.
Johnson & Johnson (JNJ) has announced a settlement of $6.475 billion to resolve lawsuits related to ovarian cancer caused by cosmetic talc. The plan includes a three-month period for ovarian cancer claimants to vote on the settlement terms. If approved by 75% of claimants, the company will file for Chapter 11 bankruptcy to ensure the settlement’s confirmation. Johnson & Johnson has previously settled 95% of mesothelioma lawsuits related to talc exposure and allocated $11 billion to cover talc-related settlements.
A federal judge in New Jersey has rejected legal challenges to the Biden administration’s Medicare drug price negotiations from Johnson & Johnson and Bristol Myers Squibb. The ruling is a significant victory for the administration, as it strengthens the constitutionality of the program and weakens the pharmaceutical industry’s strategy of seeking varying decisions in lower courts. The ruling will allow the government to negotiate lower drug prices for seniors under the Inflation Reduction Act, potentially impacting drugmakers’ profits.
Despite its continued underperformance in the healthcare sector, JNJ remains a fundamentally strong company with robust profitability and a well-diversified business. Its focus on Innovative Medicine and MedTech segments, along with recent acquisitions in cardiology, provides growth opportunities. While challenges related to Stelara biosimilars and talc-related liabilities persist, JNJ’s strong balance sheet and commitment to M&A provide a solid foundation. Investors with a value and income focus may find JNJ’s current levels attractive, offering a potentially favorable risk/reward entry point.
